Patrys Limited (PAB.AX)
AUD 0.0
(0.0%)
AUD 0.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 1.39 Million AUD | -51.11% |
| 2023 | 2.85 Million AUD | 10270.57% |
| 2022 | 27.5 Thousand AUD | 0.0% |
| 2021 | 27.5 Thousand AUD | 0.0% |
| 2020 | 27.5 Thousand AUD | -96.74% |
| 2019 | 844.36 Thousand AUD | 62.21% |
| 2018 | 520.52 Thousand AUD | 877.27% |
| 2017 | 53.26 Thousand AUD | -80.63% |
| 2016 | 274.97 Thousand AUD | -87.64% |
| 2015 | 2.22 Million AUD | 192.82% |
| 2014 | 759.68 Thousand AUD | 28643.21% |
| 2013 | 2643.00 AUD | -45.52% |
| 2012 | 4851.00 AUD | -36.16% |
| 2011 | 7599.00 AUD | 63.28% |
| 2010 | 4654.00 AUD | 24.61% |
| 2009 | 3735.00 AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 669.43 Thousand AUD | 0.0% |
| 2024 FY | - AUD | -100.0% |
| 2024 Q4 | 724.72 Thousand AUD | 0.0% |
| 2023 Q2 | 1.82 Million AUD | 0.0% |
| 2023 Q4 | 1.02 Million AUD | 0.0% |
| 2023 FY | 2.85 Million AUD | 10270.57% |
| 2022 Q2 | 13.75 Thousand AUD | 0.0% |
| 2022 Q4 | 13.75 Thousand AUD | 0.0% |
| 2022 FY | 27.5 Thousand AUD | 0.0% |
| 2021 Q4 | 13.75 Thousand AUD | 0.0% |
| 2021 Q2 | 13.75 Thousand AUD | 0.0% |
| 2021 FY | 27.5 Thousand AUD | 0.0% |
| 2020 FY | 27.5 Thousand AUD | -96.74% |
| 2020 Q4 | 13.75 Thousand AUD | 0.0% |
| 2020 Q2 | 13.75 Thousand AUD | 0.0% |
| 2019 Q2 | 218.6 Thousand AUD | 0.0% |
| 2019 FY | 844.36 Thousand AUD | 62.21% |
| 2019 Q4 | 13.75 Thousand AUD | 0.0% |
| 2018 Q4 | 295.76 Thousand AUD | 0.0% |
| 2018 Q2 | 224.76 Thousand AUD | 0.0% |
| 2018 FY | 520.52 Thousand AUD | 877.27% |
| 2017 Q2 | 320.35 Thousand AUD | 0.0% |
| 2017 FY | 53.26 Thousand AUD | -80.63% |
| 2017 Q4 | 211.37 Thousand AUD | 0.0% |
| 2016 Q2 | 587.23 Thousand AUD | 0.0% |
| 2016 FY | 274.97 Thousand AUD | -87.64% |
| 2016 Q4 | 280.41 Thousand AUD | 0.0% |
| 2015 FY | 2.22 Million AUD | 192.82% |
| 2015 Q4 | 998.71 Thousand AUD | 0.0% |
| 2015 Q2 | 1.22 Million AUD | 0.0% |
| 2014 Q4 | 39.07 Thousand AUD | 0.0% |
| 2014 Q2 | 720.61 Thousand AUD | 0.0% |
| 2014 FY | 759.68 Thousand AUD | 28643.21% |
| 2013 Q3 | 660.75 AUD | -99.93% |
| 2013 Q2 | 893.76 Thousand AUD | 73597.13% |
| 2013 FY | 2643.00 AUD | -45.52% |
| 2013 Q1 | 1212.75 AUD | 0.0% |
| 2013 Q4 | 86.62 Thousand AUD | 13010.4% |
| 2012 Q1 | 1899.75 AUD | 0.0% |
| 2012 Q4 | 1212.75 AUD | 0.0% |
| 2012 FY | 4851.00 AUD | -36.16% |
| 2012 Q2 | 1212.75 AUD | -36.16% |
| 2012 Q3 | 1212.75 AUD | 0.0% |
| 2011 Q4 | 1899.75 AUD | 0.0% |
| 2011 Q1 | 1163.50 AUD | 0.0% |
| 2011 Q2 | 1899.75 AUD | 63.28% |
| 2011 Q3 | 1899.75 AUD | 0.0% |
| 2011 FY | 7599.00 AUD | 63.28% |
| 2010 Q3 | 1163.50 AUD | 0.0% |
| 2010 FY | 4654.00 AUD | 24.61% |
| 2010 Q1 | 933.75 AUD | 0.0% |
| 2010 Q2 | 1163.50 AUD | 24.61% |
| 2010 Q4 | 1163.50 AUD | 0.0% |
| 2009 Q1 | - AUD | 0.0% |
| 2009 FY | 3735.00 AUD | 0.0% |
| 2009 Q4 | 933.75 AUD | 0.0% |
| 2009 Q2 | 933.75 AUD | 0.0% |
| 2009 Q3 | 933.75 AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2008 Q3 | - AUD | 0.0% |
| 2008 Q2 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | 19.774% |
| Acrux Limited | 5.09 Million AUD | 72.615% |
| Amplia Therapeutics Limited | 4.45 Million AUD | 68.69% |
| Biome Australia Limited | 13 Million AUD | 89.283% |
| BTC Health Limited | 16.36 Thousand AUD | -8421.779% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 81.306% |
| CSL Limited | 22.41 Billion AUD | 99.994% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 87.884% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 98.419% |
| Noxopharm Limited | 2.4 Million AUD | 41.917% |
| PharmAust Limited | - AUD | -Infinity% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -56.271% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 62.445% |
| PYC Therapeutics Limited | 22.05 Million AUD | 93.68% |
| Race Oncology Limited | 4 Million AUD | 65.176% |
| Starpharma Holdings Limited | 8.28 Million AUD | 83.181% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 97.902% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -131.658% |
| Memphasys Limited | 60 Thousand AUD | -2223.605% |
| Nyrada Inc. | - AUD | -Infinity% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.719% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -7510.06% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -1368.282% |
| Dimerix Limited | 583.47 Thousand AUD | -138.94% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 99.399% |
| Orthocell Limited | 5.31 Million AUD | 73.771% |
| Imugene Limited | - AUD | -Infinity% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 39.794% |
| Immutep Limited | 3.5 Million AUD | 60.232% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -8100.959% |
| Alterity Therapeutics Limited | 4.01 Million AUD | 65.313% |
| Nanollose Limited | 12.5 Thousand AUD | -11052.412% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -15.006% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -11.393% |
| Biotron Limited | - AUD | -Infinity% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -365.92% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -815.767% |
| AnteoTech Limited | 460.39 Thousand AUD | -202.818% |
| Hexima Limited | - AUD | -Infinity% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -2018.789% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -194.406% |
| Actinogen Medical Limited | 9.93 Million AUD | 85.962% |
| Immuron Limited | 4.9 Million AUD | 71.564% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 46.336% |